| Identification | More | [Name]
3-Mercaptopropionic acid | [CAS]
107-96-0 | [Synonyms]
3-MERCAPTO PROPIONATE
3-MERCAPTOPROPIONIC ACID
3-MPA
BETA-MERCAPTOPROPIONIC ACID
B-THIOPROPIONIC ACID
β-Mercaptopropionic acid
PROPANOIC ACID, 3-MERCAPTO
PROPONOIC ACID, 3-MERCAPTO
3-Mercaptopropanoic acid
3-mercapto-propanoicaci
3-mercaptopropanoicacid
3-mercapto-Propanoicacid
3-mercaptopropionic
3-mercapto-propionicaci
3-mercpato-propionicaci
3-Sulfanylpropanoic acid
3-Thiopropionic acid
3-thiopropionicacid
acidemercapto-3propionique
beta-mercaptopropanoicacid | [EINECS(EC#)]
203-537-0 | [Molecular Formula]
C3H6O2S | [MDL Number]
MFCD00004897 | [Molecular Weight]
106.14 | [MOL File]
107-96-0.mol |
| Chemical Properties | Back Directory | [Appearance]
clear colourless to yellowish liquid after melting | [Melting point ]
15-18 °C (lit.) | [Boiling point ]
110-111 °C/15 mmHg (lit.) | [density ]
1.218 g/mL at 25 °C(lit.)
| [vapor pressure ]
0.04 mm Hg ( 20 °C)
| [FEMA ]
4587 | 3-MERCAPTOPROPIONIC ACID | [refractive index ]
n20/D 1.492(lit.)
| [Fp ]
201 °F
| [storage temp. ]
Store below +30°C. | [solubility ]
Chloroform (Slightly), Ethyl Acetate (Slightly), Methanol (Slightly) | [form ]
Crystalline Powder, Crystals, and/or Chunks | [pka]
pK1:;pK2:10.84(SH) (25°C) | [color ]
White | [Specific Gravity]
1.218 | [Odor]
sulfurous roasted | [PH]
2 (120g/l, H2O, 20℃) | [explosive limit]
1.60%(V) | [Odor Type]
sulfurous | [Water Solubility ]
soluble | [Sensitive ]
Air Sensitive & Hygroscopic | [JECFA Number]
1936 | [BRN ]
773807 | [Stability:]
Air Sensitive, Hygroscopic | [InChIKey]
DKIDEFUBRARXTE-UHFFFAOYSA-N | [LogP]
-2.3 at 22℃ | [CAS DataBase Reference]
107-96-0(CAS DataBase Reference) | [NIST Chemistry Reference]
3-Thiolpropanoic acid(107-96-0) | [EPA Substance Registry System]
107-96-0(EPA Substance) |
| Safety Data | Back Directory | [Hazard Codes ]
T | [Risk Statements ]
R25:Toxic if swallowed.
R34:Causes burns.
R23/24/25:Toxic by inhalation, in contact with skin and if swallowed . | [Safety Statements ]
S7:Keep container tightly closed .
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection .
S45:In case of accident or if you feel unwell, seek medical advice immediately (show label where possible) . | [RIDADR ]
UN 2922 8/PG 2
| [WGK Germany ]
1
| [RTECS ]
UF5270000
| [F ]
10-13 | [Autoignition Temperature]
662 °F | [TSCA ]
Yes | [HazardClass ]
8 | [PackingGroup ]
III | [HS Code ]
29309070 | [Hazardous Substances Data]
107-96-0(Hazardous Substances Data) | [Toxicity]
LD50 orally in Rabbit: 96 mg/kg |
| Hazard Information | Back Directory | [Chemical Properties]
clear colourless to yellowish liquid after melting | [Uses]
A compound suitable for amino acid analysis by means of OPA | [Definition]
ChEBI: A mercaptopropanoic acid that is propanoic acid carrying a sulfanyl group at position 3. | [General Description]
3-Mercaptopropionic acid (3-MPA) is used as a self-assembled monolayer (SAM) with a thiol and carboxylic groups. It has short carbon chains and is mainly used as a capping agent on a variety of nanoparticles. | [Biological Activity]
3-Mercaptopropionic acid is a blocking drug that causes an increase in sleep and a decrease in wakefulness. A related finding is that nipecotic acid also increases the time needed for isoflurane to induce loss of consciousness, whereas 3-mercaptopropionic acid decreases anesthesia induction time[1].
| [References]
[1] Thakkar, M. and R. McCarley. “Neurochemistry of Sleep and Wakefulness: Histamine in the control of sleep–wakefulness.”Basic Neurochemistry (Eighth Edition) (2012).
|
| Questions And Answer | Back Directory | [Anti-cancer properties]
3-Mercaptopropionic acid is a liquid, and doses between 30 and 60 mg/kg can be used for IP seizure induction throughout development. 3-mercaptopropionic acid (3-MPA) is a convulsant and potent GAD1 inhibitor, which could inhibit the migration and invasiveness of oral cancer cells. Considering that inhibition of GAD1 impaired GABA-mediated immunosuppression, 3-MPA was also demonstrated to synergize with ICB treatment to exert better anti-tumor efficacy. Such a combination strategy could benefit the treatment of cancer types with elevated GAD1 expression. Since 3-MPA has not been approved for clinical use, it is urgent to discover novel GAD1 inhibitors that are more applicable to future clinical studies.
|
|
|